FDA Adverse Event Death Summary report: N

RAPIDPOINT 500 BLOOD GAS SYSTEM

MDR report key: 11665418 · Received April 14, 2021

Report

Report Number
3002637618-2021-00026
Event Type
Death
Date Received
April 14, 2021
Date of Event
March 24, 2021
Report Date
May 7, 2021
Manufacturer
SIEMENS HEALTHCARE DIAGNOSTICS
Product Code
CHL
PMA / PMN Number
K122539
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
AU
Reporter Occupation
NURSE

Narratives

Additional Manufacturer Narrative · 0

SIEMENS HAS COMPLETED THE INVESTIGATION: BASED ON THE DATA PRESENTED IN THIS INVESTIGATION, THE CO-OXIMETRY OPTICAL SUBSYSTEM RESPONSIBLE FOR THE MEASUREMENT OF THB APPEARED STABLE AND FUNCTIONING AS EXPECTED. THIS WAS DETERMINED BASED ON THE CO-OX QUALITY CHECKS, PERFORMANCE WITH AQC (THB), LACK OF ANY CO-OX RELATED CALIBRATION DRIFTS OR DIAGNOSTIC ERRORS DURING THE TIME PERIOD OF THE ESCALATED EVENT. THE CO-OX UNIT AND THE SPECTROPHOTOMETERS WERE WORKING AS EXPECTED. THE REPORTED THB IS BASED ON MEASURING THE BLOOD CELLS AS DELIVERED TO THE CO-OX SLIDE CELL. FOR AN ACCURATE MEASUREMENT OF THB, THOROUGH MIXING AND ROTATING OF THE RED BLOOD CELLS IMMEDIATELY BEFORE ANALYSIS IS REQUIRED. A DEFINITE ROOT-CAUSE FOR THE OBSERVED DISCREPANCY IN THB RESULTS BETWEEN SN (B)(6) AND SN (B)(6) COULD NOT BE IDENTIFIED.

Additional Manufacturer Narrative · 1

THE DATA FILES HAVE BEEN RECEIVED FROM THE CUSTOMER FOR INVESTIGATION. THE CAUSE OF THE DISCREPANT TOTAL HEMOGLOBIN RESULTS IS UNKNOWN.

Description of Event or Problem · 1

THE CUSTOMER REPORTED DISCREPANT TOTAL HEMOGLOBIN RESULTS ON ONE PATIENT WHEN RUN ON TWO RP 500 INSTRUMENTS. THE CUSTOMER STATED THAT THE PATIENT DIED FROM COVID-19 AFTER ECMO TREATMENT. THE CUSTOMER CONFIRMED THEY ARE NOT ALLEGING THE RP 500 CAUSED OR CONTRIBUTED TO THE DEATH OF THE PATIENT AND THAT THE PATIENT WAS NOT INCORRECTLY TREATED BASED ON THE RP 500 RESULTS.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
565458 RAPIDPOINT 500 BLOOD GAS SYSTEM RP 500 CHL SIEMENS HEALTHCARE DIAGNOSTICS

Patients

Seq Age Sex Outcome Treatment
1 60 YR